NasdaqGS:MASIMedical Equipment
Masimo (MASI) Valuation After FDA Clears O3 Platform for Broader Critical Care Applications
Masimo (MASI) just landed a significant regulatory win as the company received FDA 510(k) clearance for expanded indications of its O3 Regional Oximetry platform. The clearance now covers both cerebral and somatic applications for every patient age group, including the pediatric and neonatal segments. For investors, this is more than just another product update; it has the potential to broaden Masimo’s reach in critical care settings, increasing the clinical appeal and adoption of its Root...